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tissue, estimated by neck circum-
ference (NC), is a unique fat depot
that may confer additional risk for meta-
bolic risk factors over generalized and
central adiposity (1). Using a prospective
study design, we now evaluate whether
NC improves the prediction of incident
cardiovascular disease risk factors over
BMI and waist circumference (2).
Framingham Heart Study participants
(n 5 2,732; 54% women; mean age, 57
years) were followed for ;10 years (1995–
2008)forthedevelopmentoftype2diabetes
(fastingplasmaglucose$126mg/dLortreat-
ment), hypertension, low HDL cholesterol
(,40mg/dL,men;,50mg/dL,women),
and high triglycerides ($150 mg/dL
or lipid treatment). NC, BMI, and waist
circumference were standardized within
each sex to a mean of zero and an SD of
one. Logistic regression models, adjusted
forage,sex,andsmoking,wereusedtotest
the association between 1 SD increment of
NC with each outcome. C-statistics were
calculated to assess the impact of adding
NC to baseline models, and the net re-
classiﬁcation improvement (NRI) statistic
was calculated to assess risk reclassiﬁcation
improvement (low, 0–1.9%; medium, 2.0–
7.9%; high, $8% risk categories) (3,4).
Inbaselinemodels,NCwasassociated
(P,0.05)withalloutcomes.Afterfurther
adjustment for BMI and waist circumfer-
ence, NC remained associated only with
type 2 diabetes (n 5 182, odds ratio [OR]
5 1.57, 95% CI [1.24–1.98], P 5
0.0002). In this model, the OR for BMI
was 1.03 (95% CI [0.73–1.45], P 5
0.88), and the OR for waist circumference
was 1.48(95% CI[1.05–2.10], P50.03).
Additional adjustment for baseline fasting
blood glucose resulted in an OR for NC of
1.42 (95% CI [1.09–1.86], P 5 0.01).
When NC was added to a model
containing an established type 2 diabetes
risk score (5), the OR for type 2 diabetes
was1.36(95%CI[1.12–1.66],P50.002),
and the NRI was 10.2% (P , 0.0001).
WhenNCwasaddedtoamodelcontaining
the individual clinical characteristics used
toderivethetype2diabetesriskscore(age,
sex, parental history of type 2 diabetes,
BMI, hypertension, HDL cholesterol, and
fastingplasmaglucose),theORwassimilar
(OR1.53,95%CI[1.22–1.92],P50.0003).
NC had a stronger effect on the
incidence of type 2 diabetes in women
(OR 5 2.77, 95% CI [2.18–3.53], P ,
0.0001) compared with men (OR 5
1.76, 95% CI [1.43–2.15], P , 0.0001)
(Pinteraction 5 0.006).
For type 2 diabetes, the addition of
NC to a model containing baseline co-
variates and BMI resulted in a change in
the C-statistic from 0.743 to 0.766 (P 5
0.004) and an NRI of 7.4% (P 5 0.01).
When NC was added to a model with base-
linelevelsoffastingplasmaglucoseandBMI,
theC-statisticincreasedfrom0.885to0.891
(P 5 0.01), and the NRI was 4.5%
(P 5 0.03). Similar results were observed
when waist circumference was substituted
for BMI. When NC was added to a model
with BMI and waist circumference, the
C-statistic increased from 0.754 to 0.772 (P
5 0.01), and the NRI was 4.9% (P 5 0.10).
NC is associated with incident type 2
diabetes and a clinically meaningful im-
provement in the NRI. Our results are
limitedbythesinglefastingplasmaglucose
measure and the exclusion of those who
did not return for follow-up. Whether
measurement of NC improves type 2 di-
abetes prediction over traditional adiposity
measures warrants further investigation.
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